RecruitingAcute Lymphocytic Leukemia (ALL)
Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical research study is to learn if obecabtagene autoleucel (obe-cel) can help to control newly diagnosed, high-risk B-cell ALL when given as consolidation therapy. Consolidation therapy is given after the first phase of treatment.
Sponsor: M.D. Anderson Cancer Center
You may qualify if…
- ✓ I. Patients of age .18 years with high-risk B-cell ALL in first remission and \<5% BM blasts with at least one high-risk feature defined as:
- ✓ 1. Ph-negative B-cell ALL:
- ✓ 1. KMT2A rearranged ALL
- ✓ 2. Complex cytogenetics as per NCCN 2022
- ✓ 3. Low-hypodiploidy/tetraploidy
- ✓ 4. Philadelphia-like ALL (based on CRLF2 overexpression or recurrent Ph-like genetic fusions)
- ✓ 5. TP53 mutation (variant allele fraction \>2%)
- ✓ 6. Persistent MRD by flow cytometry and/or NGS
You may not qualify if…
- ✕ 1. Pregnant or lactating; women of child-bearing potential (WOCBP) must have negative pregnancy test. WOCBP defined as not post-menopausal for 12 months or no previous surgical sterilization.
- ✕ 2. Patients with history of Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV) infections, even if under control. (Patients with Hepatitis B core antibody positive alone will not be an exclusion factor if HBV DNA PCR is negative).
- ✕ 3. Active and uncontrolled disease/infection as judged by the treating physician
- ✕ 4. Unable or unwilling to sign the consent form
Where it's recruiting
Texas
Houston
Source: ClinicalTrials.gov · NCT07053059 · last updated 2026-08-12